Get the latest news, insights, and market updates on CYTK (Cytokinetics, Incorporated). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Cytokinetics to Participate in March Investor Conferences
SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company management team will participate in the following investor conferences in March: Leerink 2026 Global Healthcare Conference: Fireside chat on Monday, March 9, 2026 at 9:20 AM Eastern Time in Miami Beach, FL.Citizens 2026 Life Sciences Conference: Fireside chat on Tuesday, March 10, 2026 at 9:00 AM Eastern Time in Miami Beach, FL.2026 Jefferies Biote Mar 2, 2026 - $CYTK
Assessing Cytokinetics (CYTK) Valuation After Recent Share Price Weakness And Aficamten Expectations
Cytokinetics stock overview Cytokinetics (CYTK) has been drawing attention as investors reassess its late stage pipeline in muscle focused therapies, alongside its current share price of US$62.22 and a mix of short term and longer term total returns. See our latest analysis for Cytokinetics. While the 1 day and 7 day share price returns of a 0.65% decline and an 8.42% decline suggest recent momentum has cooled, the 1 year total shareholder return of 35.26% and 5 year total shareholder return... Mar 2, 2026 - $CYTK
Cytokinetics Q4 Earnings Call Highlights
Cytokinetics (NASDAQ:CYTK) used its fourth-quarter 2025 earnings call to highlight a major transition for the company: the approval and initial U.S. launch execution of MYQORZO for adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM), alongside advancing late-stage clinical programs Feb 25, 2026 - $CYTK
Cytokinetics (CYTK) Reports Q4 Loss, Beats Revenue Estimates
Cytokinetics (CYTK) delivered earnings and revenue surprises of -1.63% and +356.43%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock? Feb 25, 2026 - $CYTK
Cytokinetics (CYTK) Q4 2025 Earnings Transcript
Robert I. Blum, President and Chief Executive Officer, will begin with an overview of the quarter and recent developments. Fady Malik, EVP of R&D, and Stuart Kupfer, SVP and Chief Medical Officer, will provide updates related to our clinical development programs. Sung H. Lee, EVP and Chief Financial Officer, will provide a financial overview of 2025 and discuss our 2026 financial guidance. Feb 24, 2026 - $CYTK
Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update
MYQORZO® Approved for Adults with Symptomatic Obstructive HCM in U.S., China and Europe; U.S. Launch Underway with First Prescriptions Dispensed within Days of Drug Availability Supplemental NDA for MAPLE-HCM Submitted to FDA in Q1 2026 Expect to Share Topline Results from ACACIA-HCM in Q2 2026 Company Provides 2026 Financial Guidance;~$1.2 Billion in Cash, Cash Equivalents and Investments as of December 31, 2025 SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorp Feb 24, 2026 - $CYTK
Cytokinetics: Q4 Earnings Snapshot
SOUTH SAN FRANCISCO, Calif. AP) — Cytokinetics Inc. CYTK) on Tuesday reported a loss of $183 million in its fourth quarter. Feb 24, 2026 - $CYTK
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple